The JO25567 study was the first to obtain clinically meaningful data that confirmed the efficacy of combined bevacizumab and EGFR-TKI in the first-line management of advanced NSCLC with EGFR-activating mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.